Lurbinectedin is a drug that has shown promise in the treatment of ovarian cancer. It is a selective inhibitor of RNA polymerase II and induces DNA damage, leading to apoptosis in cancer cells. The drug is currently being studied in clinical trials for its efficacy in treating various types of cancer, including ovarian cancer .
A phase II clinical trial (NCT02421588) investigated the efficacy of lurbinectedin in treating patients with relapsed platinum-resistant ovarian cancer. The study found that lurbinectedin had a response rate of 22.2%, with a median progression-free survival of 3.5 months .
Another study published in the journal Gynecologic Oncology evaluated the antitumor activity of lurbinectedin in preclinical models of ovarian cancer. The study found that lurbinectedin exhibited significant antitumor activity against ovarian cancer cell lines and xenograft models, suggesting its potential as a therapeutic option for ovarian cancer .
In conclusion, the available evidence suggests that lurbinectedin has potential as a treatment option for ovarian cancer. However, further clinical trials are needed to fully evaluate its efficacy and safety in treating this disease.